Infectious Diseases - Product Pipeline - Products - 世之源生物科技有限责任公司

UB-621

Product Description

UB-621 is a fully human, original monoclonal antibody formulated for subcutaneous injection, developed for the treatment of human herpes simplex virus (HSV) infections.

Unlike traditional small-molecule antiviral drugs, UB-621 specifically binds to glycoprotein D on the viral envelope, blocking the interaction between the virus and host cell receptors. This prevents the virus from entering host cells and also disrupts cell-to-cell transmission of HSV. Because UB-621 targets the external pathogen directly, it does not interfere with the body's normal immune function.

UB-621

Pharmacological
Mechanism

Genital herpes virus (HSV) is transmitted through epithelial tissues and establishes latency within the nervous system. It can later reactivate and travel back to the skin or mucosa, causing recurrent outbreaks — a common issue for most patients. UB-621 works by binding specifically to glycoprotein D (gD) on the herpes virus. This binding directly interferes with the virus’s ability to attach to human cells and inhibits its capacity to spread within tissues, thereby suppressing infectivity.

UB-621

Current Disease
Landscape

Genital herpes currently affects nearly 500 million people worldwide, with approximately 180 million cases in China alone. The annual growth rate is around 0.7%.Current treatment mainly relies on conventional antiviral drugs to relieve symptoms, but the suppressive effect is limited and recurrences are common. Approximately 13–15% of patients experience more than six recurrences per year. Patients are often required to take daily medication continuously, which significantly impacts their quality of life.

5billion

Global population distribution of genital herpes
180million patients

Population affected domestically
0.7%

Annual growth rate of patients

Challenges of Conventional Therapies for Genital Herpes:

Oral and topical treatments show variable efficacy among individuals
Poor effectiveness against known viral mutants
Unable to prevent symptom recurrence
Require continuous daily dosing without interruption
Associated side effects include nausea, headaches, hallucinations, generalized seizures, etc.
Cannot achieve complete cure

Currently, there are no available medications on the market that can effectively eradicate recurrent genital herpes

UB-621

Product Overview

UB-621 is a breakthrough innovative monoclonal antibody that makes the suppression of genital herpes recurrence possible.

Efficacy Comparison of UB-621 and Conventional Drug Acyclovir in Mouse Models:

UB-621

UB-621 as a monotherapy demonstrated consistent therapeutic effects
Significantly reduced recurrence frequency
Effective with dosing once every 4 weeks
Achieved 100% survival rate in animal studies
Potential to achieve complete cure

UB-621

Product Advantages

Phase I clinical data demonstrated an excellent safety profile, with all three adverse events reported during the trial related only to injection site reactions such as redness and itching.

Cohort	Clinical Trial Event Summary
Cohort	Adverse Events	Serious Adverse Events	Dose-Limiting Toxicity	Anti-Drug Antibodies
Cohort 1 (0.1 mg/kg)	0	0	0	0
Cohort 2 (0.3 mg/kg)	0	0	0	0
Cohort 3 (1 mg/kg)	0	0	0	0
Cohort 4 (3 mg/kg)	2	0	0	0
Cohort 5 (5 mg/kg)	1	0	0	0

Based on the trial data, doses of UB-621 at 3 mg or higher can maintain therapeutic effects for up to two months, demonstrating the potential for developing a long-acting dosing regimen.

Dose (mg/kg)	Half-life (days)
0.1	23.2
0.3	28.2
1	26
3	25.7
5	23.5

UB-621

Indication Potential

Additional Therapeutic Potentials:

Recurrent genital herpes
Drug-resistant HSV-1 and HSV-2 infections
Vertical transmission of herpes simplex virus type 2 (HSV-2) from mother to child
Herpes keratitis caused by HSV-1